When high-risk neuroblastoma patients were stratified into two clinically distinct subtypes, high-risk neuroblastoma (HR-NB) and ultra-high-risk neuroblastoma (UHR-NB), as described previously [15], we observed that CNTN1 expression was significantly higher in HR-NB tumors compared to UHR-NB tumors, while MYCN expression was significantly higher in UHR-NB tumors compared to HR-NB tumors in both datasets (Figure 1F,H). This evidence concerns the gene MYCN and neuroblastoma.